IN8bio, Inc.
INAB
$1.75
-$0.03-1.69%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.86M | 2.71M | 2.69M | 2.63M | 2.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.97M | 5.20M | 5.66M | 6.22M | 6.04M |
| Operating Income | -3.97M | -5.20M | -5.66M | -6.22M | -6.04M |
| Income Before Tax | -3.85M | -5.09M | -5.55M | -6.16M | -7.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.85M | -5.09M | -5.55M | -6.16M | -7.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.85M | -5.09M | -5.55M | -6.16M | -7.09M |
| EBIT | -3.97M | -5.20M | -5.66M | -6.22M | -6.04M |
| EBITDA | -3.60M | -4.66M | -5.16M | -5.74M | -5.56M |
| EPS Basic | -0.85 | -1.24 | -1.99 | -2.40 | -4.49 |
| Normalized Basic EPS | -0.53 | -0.77 | -1.25 | -1.50 | -2.38 |
| EPS Diluted | -0.85 | -1.24 | -1.99 | -2.40 | -4.49 |
| Normalized Diluted EPS | -0.53 | -0.77 | -1.25 | -1.50 | -2.38 |
| Average Basic Shares Outstanding | 4.54M | 4.12M | 2.78M | 2.57M | 1.58M |
| Average Diluted Shares Outstanding | 4.54M | 4.12M | 2.78M | 2.57M | 1.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |